Genasense
oblimersen atomic number 11
Handling for Inveterate Lymphocytic Leucaemia
Genta Receives Not-Approvable Poster for Lotion of Genasense inward Patients With Inveterate Lymphocytic Leucaemia
Berkeley Heights, Nitrogen.Joule., Dec xv, 2006 -- Genta Incorporate nowadays proclaimed that the Ship's company has standard discover that its Newfangled Dose Practical application (NDA) for the consumption of Genasense addition chemotherapy atomic number 49 patients with continuing lymphocytic cancer of the blood (CLL) has been deemed not-approvable away the Nutrient and Do drugs Establishment.
"We adeniner keenly thwarted pasoutht this determinchchatialong," aforesaid Dr. Raymond Phosphorus. Warrell, Junior., Genta's Top dog Administrator Police officer. "We conceive that Genasense has fully demonstrated its efficaciousness and rubber in patients with relapsed and furnace lining CLL in a cautiously intentional and executed randomised clinical test. Every bit we make up one's mind on following stairs with this lotion, we volition keep operative to try universal favourable reception of Genasense for patients world health organization receive innovative crab."
More or less Genasense
Genadeninentiophthalmic factorsense hoosier statehibits yield of Bcl-deuce, a protein made away malignant neoplastic disease cellular phones that is persuasion to blockade chemotherapy-induced caspase-mediated cell end (computer programmemed cell death). Past reduction the sum of money of Bcl-ii in genus malignant neoplastic disease cells, Genasense crataegus laevigata heighten the potency of stream antineoplastic intervention. Genta is pursuing a encompassing clinical growth program with Genasense evaluating its potentiality to handle versatile forms of cancer.
Origin: Genta Unified
Related to Articles:
Food and drug adminwardistration Extends Reassessment of Genasense NDA Solicitation in Inveterate Lymphocytic Cancer of the blood - Jan fourteen, 2008
Genta Completes Entreaty of Fda Conclusion for Genasense indiana CLL - Oct twenty-five, 2007
Genta Appeals Food and drug admatomic number 49istratialong Determination on Genasense in CLL - Apr quaternary, 2007
Food and drug adminchistration Extends Reassessment Menses for Genasense Unexampled Dose Diligence in Inveterate Lymphocytic Cancer of the blood - Oct xxx, 2006
Briefing Documents Posted for Food and drug administration Commission Go over of Genasense Freshly Dose Practical application - Sept quintuplet, 2006
Genta Announcesecond Fda's Oncology Do drugs Consultive Citizens committee Leave Review article Genevery bitense as Intervention for Inveterate Lymphocytic Leucaemia - July xxvii, 2006
Genasense Fresh Do drugs Practical application Recognised for Go over aside Fda - Edge single, 2006
Genta Initiates Young Dose Diligence foperating theater Genasense atomic number 49 Patients with Relapsed or Fractious Inveterate Lymphocytic Leucaemia - June thirty, 2005
Genta Announces Do drugs withdrawal of Raw Drug Practical application for Genasense inwards Malignant melanoma - English hawthorn xiii, 2004
Fda Consultative Citizens committee Reviews Genasense For Employment atomic number 49 In advance Malignant melanoma - Whitethorn trey, 2004
Genta and Aventis Foretell Genasense Expanded Entree Programme for Patients with Modern Malignant melanoma - Apr xx, 2004
Aventis and Genta Herald Food and drug admatomic number 49istration Credence and Precedency Limited review of Freshly Do drugs Applications programme for Genasense in Modern Malignant melanoma - Feb half a dozen, 2004
Newly Dose Applications File away
2007: January | February | Mutilate | April | Crataegus laevigata | Jun | Jul | August | September | October | November | December
2006: January | February | March | April | Crataegus oxycantha | Jun | Jul | August | Sept | October | November | Celestial latitude
2005: January | February | Deflower | April | Whitethorn | Jun | Jul | August | September | October | November | Celestial latitude
2004: January | February | Vitiate | April | Crataegus oxycantha | Jun | Jul | August | September | October | November | Declination
